|Year : 2018 | Volume
| Issue : 3 | Page : 257-258
Demonstration of 68Ga-prostate-specific membrane antigen uptake in metastatic pancreatic neuroendocrine tumor
Meghana Prabhu, Nishikant Avinash Damle, Ravikant Gupta, Saurabh Arora, Sreedharan Thankarajan Arunraj, Chandrasekhar Bal
Department of Nuclear Medicine, AIIMS, New Delhi, India
|Date of Web Publication||11-Jun-2018|
Nishikant Avinash Damle
Department of Nuclear Medicine, AIIMS, Ansari Nagar, New Delhi - 110 029
Source of Support: None, Conflict of Interest: None
| Abstract|| |
We present the case of a 47-year-old female with metastatic pancreatic neuroendocrine tumor (NET). The patient was treated with long-acting octreotide which failed to halt disease progression. The patient was being considered for 177Lu-peptide receptor radionuclide therapy, and a 68Ga-DOTANOC positron emission tomography-computed tomography (PET-CT) was acquired initially, which showed good uptake in the primary and metastatic lesions. Metastatic pancreatic NETs have limited treatment options, and given the background that these tumors are highly vascular and prostate-specific membrane antigen (PSMA) expression is known in the endothelium of tumor neovasculature, we decided to perform a 68Ga-PSMA-HBED-CC PET-CT scan. It revealed radiotracer uptake in the metastatic liver lesions although not as high as 68Ga-DOTANOC-PET-CT. PSMA expression needs to be researched further, especially in high-grade NETs where somatostatin expression may be poor.
Keywords: 68Ga-prostate-specific membrane antigen positron emission tomography-computed tomography, neuroendocrine tumor, theranostics
|How to cite this article:|
Prabhu M, Damle NA, Gupta R, Arora S, Arunraj ST, Bal C. Demonstration of 68Ga-prostate-specific membrane antigen uptake in metastatic pancreatic neuroendocrine tumor. Indian J Nucl Med 2018;33:257-8
|How to cite this URL:|
Prabhu M, Damle NA, Gupta R, Arora S, Arunraj ST, Bal C. Demonstration of 68Ga-prostate-specific membrane antigen uptake in metastatic pancreatic neuroendocrine tumor. Indian J Nucl Med [serial online] 2018 [cited 2019 Dec 5];33:257-8. Available from: http://www.ijnm.in/text.asp?2018/33/3/257/234140
Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) has been extensively used in the management of patients with prostate cancer. This tracer also offers an important example of the concept of theranostics. However, PSMA expression has also been reported previously in other malignancies such as bladder, breast, gastric, colon, rectum, lung, renal cell carcinoma, hepatocellular carcinoma, multiple myeloma, and follicular lymphoma and in few nonneoplastic conditions.,,,,,,,, Very few studies have shown expression of PSMA in neuroendocrine tumors (NETs). It is well known from some earlier studies that PSMA expression is seen in the endothelium of tumor neovasculature. Since NETs have very high vascularity, PSMA expression may be seen in the same. In this case, PSMA-PET-CT showed uptake in the primary tumor in the pancreas and metastatic liver lesions. The uptake was high in the periphery of the tumor concordant with the expected distribution of neovasculature. However, the intensity of the uptake was low as compared to 68Ga-DOTANOC. The number of lesions seen on PSMA-PET/CT was much less than that seen on DOTANOC-PET/CT [Figure 1]. However, it remains to be seen how much uptake will be seen in high-grade NETs which are known to be poorly DOTANOC avid. This finding may encourage researchers to consider this modality from the theranostic point of view in a disease with limited treatment options.
|Figure 1: 68Ga-DOTANOC positron emission tomography- computed tomography (a) and 68Ga-prostate- specific membrane antigen-11 positron emission tomography-computed tomography (b) in a case of metastatic pancreatic neuroendocrine tumor, showing increased tracer uptake in multiple liver lesions. However, the intensity of uptake was less in 68Ga-prostate-specific membrane antigen when compared to 68Ga-DOTANOC images|
Click here to view
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB, et al.
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr., Wang CY, et al.
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006;30:628-36.
Vamadevan S, Le K, Shen L, Ha L, Mansberg R. Incidental prostate-specific membrane antigen uptake in a peripheral nerve sheath tumor. Clin Nucl Med 2017;42:560-2.
Chan M, Schembri GP, Hsiao E. Serous cystadenoma of the pancreas showing uptake on 68Ga PSMA PET/CT. Clin Nucl Med 2017;42:56-7.
Huang YT, Fong W, Thomas P. Rectal carcinoma on 68Ga-PSMA PET/CT. Clin Nucl Med 2016;41:e167-8.
Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga prostate-specific membrane antigen activity in metastatic non-small cell lung cancer. Clin Nucl Med 2016;41:414-6.
Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA uptake in hepatocellular carcinoma. Clin Nucl Med 2017;42:e69-70.
Sasikumar A, Joy A, Pillai MR, Nanabala R, Thomas B 68Ga-PSMA PET/CT imaging in multiple myeloma. Clin Nucl Med 2017;42:e126-7.
Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016;41:500-1.
Vamadevan S, Shetty D, Le K, Bui C, Mansberg R, Loh H, et al.
Prostate-specific membrane antigen (PSMA) avid pancreatic neuroendocrine tumor. Clin Nucl Med 2016;41:804-6.